C-kit expression in human osteosarcoma and in vitro assays

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 8, 2011, Pages 775-781

  Miiji, Luciana NO ^a   Petrilli, Antonio S ^a   Di Cesare, Sebastian ^b   Odashiro, Alexandre N ^c   Burnier, Miguel N ^b   de Toledo, Silvia R ^a   Garcia, Reynaldo Jesus ^c   Alves, Maria Teresa S ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

C kit; Immunohistochemistry; In vitro assays; Osteosarcoma; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; BONE TUMOR; CELL MOTION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KAPLAN MEIER METHOD; MALE; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; OSTEOSARCOMA; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84856736982     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fletcher CDM, Unni KK, Mertens F. World Health Organization, International Academy of Pathology: Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press 2002.
2. Unni KK, Dahlin DC. Dahlin's bone tumors: general aspects and data on 11,087 cases, 5th edn. Philadelphia: Lippincott-Raven 1996.
3. Bacci G, Ferrari S, Longhi A, Forni C, Zavatta M, Versari M, Smith K. High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation. J Pediatr Hematol Oncol 2002; 24: 27-30.
4. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus Garcia R, Camargo OP, Pena W, Péricles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Almeida MT, Borsato ML, dos Santos TM, Ortega J, Consentino E. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 2006; 24: 1161-1168.
5. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, LaQuaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11: 449-453.
6. Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S, Campanacci M. P-glycoprotein expression in osteosarcoma: a basis for riskadapted adjuvant chemotherapy. J Orthop Res 1999; 17: 629-632.
7. Benassi MS, Molendini L, Gamberi G, Sollazzo MR, Ragazzini P, Merli M, Magagnoli G, Sangiorgi L, Bacchini P, Bertoni F, Picci P. Altered G1 phase regulation in osteosarcoma. Int J Cancer 1997; 74: 518-522.
8. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-495.
9. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002; 26: 486-492.
10. Entz-Werlé N, Marcellin L, Gaub MP, Guerin E, Schneider A, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Jeanne-Pasquier C, Terrier P, Dijoud F, Oudet P, Lutz P, Babin-Boilletot A. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas. J Clin Oncol 2005; 23: 2248-2255.
11. Sulzbacher I, Birner P, Toma C, Wick N, Mazal PR. Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker. J Clin Pathol 2007; 60: 804-807.
12. Wei H, Zhao MQ, Dong W, Yang Y, Li JS. Expression of c-kit protein and mutational status of the c-kit gene in osteosarcoma and their clinicopathological significance. J Int Med Res 2008; 36: 1008-1014.
13. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004; 9: 271-281.
14. Pindolia VK, Zarowitz BJ. Imatinib mesylate, the first molecularly targeted gene suppressor. Pharmacotherapy 2002; 22: 1249-1265.
15. Yoshitani K, Honoki K, Morishita T, Kido A, Miyauchi Y, Mii Y, Takakura Y. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571 In Vivo 2003; 17: 255-258.